HTI 501

Drug Profile

HTI 501

Alternative Names: HTI-501; Recombinant human cathepsin L - Halozyme Therapeutics; rHuCAT-L

Latest Information Update: 29 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Halozyme Therapeutics
  • Class
  • Mechanism of Action Cathepsin L modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cellulite

Most Recent Events

  • 31 May 2015 HTI 501 is still in phase I/II trials for Cellulite in Mexico
  • 25 Mar 2014 Top-line efficacy & adverse events data from a phase I/II trial Cellulite released by Halozyme Therapeutics
  • 07 Aug 2013 Halozyme Therapeutics completes enrolment in its phase I/II trial for Cellulite in Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top